- Home
- PETS vs BTAI Comparison
PETS vs BTAI Comparison
Compare PETS & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- BTAI
- Stock Information
- Founded
- PETS 1996
- BTAI 2017
- Country
- PETS United States
- BTAI United States
- Employees
- PETS N/A
- BTAI N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- BTAI Health Care
- Exchange
- PETS Nasdaq
- BTAI Nasdaq
- Market Cap
- PETS 53.7M
- BTAI 52.7M
- IPO Year
- PETS N/A
- BTAI 2018
- Fundamental
- Price
- PETS $2.54
- BTAI $2.48
- Analyst Decision
- PETS Sell
- BTAI Buy
- Analyst Count
- PETS 1
- BTAI 5
- Target Price
- PETS $3.20
- BTAI $32.80
- AVG Volume (30 Days)
- PETS 113.6K
- BTAI 1.6M
- Earning Date
- PETS 11-05-2025
- BTAI 11-13-2025
- Dividend Yield
- PETS N/A
- BTAI N/A
- EPS Growth
- PETS N/A
- BTAI N/A
- EPS
- PETS 0.02
- BTAI N/A
- Revenue
- PETS $247,010,000.00
- BTAI $868,000.00
- Revenue This Year
- PETS N/A
- BTAI N/A
- Revenue Next Year
- PETS N/A
- BTAI $614.78
- P/E Ratio
- PETS $148.85
- BTAI N/A
- Revenue Growth
- PETS N/A
- BTAI N/A
- 52 Week Low
- PETS $2.45
- BTAI $1.17
- 52 Week High
- PETS $6.85
- BTAI $13.28
- Technical
- Relative Strength Index (RSI)
- PETS 36.72
- BTAI 38.09
- Support Level
- PETS $2.52
- BTAI $2.47
- Resistance Level
- PETS $2.64
- BTAI $2.70
- Average True Range (ATR)
- PETS 0.09
- BTAI 0.21
- MACD
- PETS 0.01
- BTAI -0.00
- Stochastic Oscillator
- PETS 23.75
- BTAI 9.74
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.